KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Raw Materials: 2018-2025

Historic Raw Materials for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Sep 2025 value amounting to $22.3 million.

  • Alnylam Pharmaceuticals' Raw Materials fell 0.51% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year decrease of 0.51%. This contributed to the annual value of $24.0 million for FY2024, which is 2.65% up from last year.
  • Alnylam Pharmaceuticals' Raw Materials amounted to $22.3 million in Q3 2025, which was down 2.70% from $22.9 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Raw Materials registered a high of $65.2 million during Q3 2021, and its lowest value of $14.8 million during Q4 2021.
  • For the 3-year period, Alnylam Pharmaceuticals' Raw Materials averaged around $22.7 million, with its median value being $22.9 million (2023).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Raw Materials crashed by 76.75% in 2021 and then soared by 51.25% in 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' Raw Materials (Quarterly) stood at $14.8 million in 2021, then spiked by 51.25% to $22.3 million in 2022, then climbed by 4.62% to $23.3 million in 2023, then climbed by 2.65% to $24.0 million in 2024, then decreased by 0.51% to $22.3 million in 2025.
  • Its Raw Materials was $22.3 million in Q3 2025, compared to $22.9 million in Q2 2025 and $23.4 million in Q1 2025.